Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues
Autore:
Sanchez-Lacay, JA; Lewis-Fernandez, R; Goetz, D; Blanco, C; Salman, E; Davies, S; Liebowitz, M;
Indirizzi:
New York State Psychiat Inst, New York, NY 10032 USA New York State Psychiat Inst New York NY USA 10032 New York, NY 10032 USA Columbia Univ, Dept Psychiat, New York, NY USA Columbia Univ New York NY USA mbia Univ, Dept Psychiat, New York, NY USA
Titolo Testata:
DEPRESSION AND ANXIETY
fascicolo: 3, volume: 13, anno: 2001,
pagine: 118 - 124
SICI:
1091-4269(2001)13:3<118:OTONAH>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; OUTPATIENTS; IMIPRAMINE; PLACEBO; SATISFACTION; PAROXETINE; SERTRALINE; FLUOXETINE; SYMPTOMS; WOMEN;
Keywords:
antidepressant efficacy; major depression; Hispanics; ethnopsychopharmacology; adherence; nefazodone; tolerability;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Lewis-Fernandez, R New York State Psychiat Inst, Unit 69,1051 Riverside Dr, New York, NY 10032 USA New York State Psychiat Inst Unit 69,1051 Riverside Dr New York NY USA 10032
Citazione:
J.A. Sanchez-Lacay et al., "Open trial of nefazodone among Hispanics with major depression: Efficacy, tolerability, and adherence issues", DEPRESS ANX, 13(3), 2001, pp. 118-124

Abstract

The efficacy and tolerability of nefazodone in the treatment of major depression among Spanish-monolingual Hispanics was examined ann compared to historical controls among English-speaking, predominantly non-Hispanic subjects. Fifty monolingual Hispanic outpatients with major depression? and a HAM-D-17 score greater than or equal to 18 were treated with nefazodone in a flexible-dose 8-week open-label protocol. Sixty-three percent of the intent-to-heat (ITT) sample with greater than or equal to1 efficacy visit were considered responders according to CGI-I criteria, falling within the range of response rates (58-69%) reported in sir prior nefazodone trials with non-Hispanic subjects. Significant improvement was found for the ITT and completer samples in HAM-D-17 HAM-D-28, and SCL-90 scores and in two measures of psychosocial functioning. Endpoint mean dose in the ITT sample was 379 mg/day(SD=170), also within the range of previous trials (321-472mg/day). Aaverse effects were not elevated, with only dry mouth (8%) reported by >6% of subjects. However, 42% of the sample dropped out of treatment before study teemination, usually, because of side effects or due to family or work difficulties, a higher rate than previously reported for nefazodone (21-33%). This open trial finds nefazodone to be an eficacious treatment for major depression among monolingual Hispanics, with comparable efficacy to previous controlled trials among non-Hispanic subjects. Double-blind studies are required to confirm this comparable efficacy. Mean endpoint doses and adverse effect rates similar to previous trials no not support the need for reduced noses of nefazodone among Hispanics. However, an elevated rate of treatment discontinuation threatens treatment efficacy among this population. Causes for this elevated rate require explanation, given the apparently unremarkable pattern of adverse effect reports. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:49:51